ima402
immatics
['ima402', 'immatics ']
today at 2022 we announced preclinical data for our #tcr bispecific, tcer ima402, targeting #solidtumor antigen prame, which shows enhanced anti-tumor activity in vivo &amp; a favorable safety profile in vitro. to view the news, please click here: 
Immatics is active in the discovery and development of T cell redirecting immunotherapies for the treatment of cancer
Legal notice: https://t.co/15aK63mHYH
#immaticsjobs